Antithrombin use review at Strasbourg Hospital
Part of Blood & lymphatic clinical trials.
This study looks back at patient records to see how antithrombin (a medicine that helps prevent blood clots) was used in intensive care or during surgery. It does not test a new treatment, but helps doctors understand if the medicine was given appropriately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You received antithrombin while in the intensive care unit or during an operation between January 1, 2022 and December 31, 2023
- You (or your legal representative) have not said you don't want your data used for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using long-term blood thinners (anticoagulants) in adults with severe hemophilia A, a bleeding disorder. It aims to understand if this treatment can be safe and effective for patients who may need it.
This trial uses stored blood samples to see how well different lab tests measure clotting when someone has a factor deficiency (like low levels of clotting proteins) or liver damage. It may help doctors choose the most accurate test for these situations.
This study compares two types of blood thinners (DOACs like rivaroxaban or apixaban, and vitamin K blockers like warfarin) in people with antiphospholipid syndrome who had a vein clot. The goal is to see which one works better at preventing future clots without causing more bleeding.
This Phase 2 trial studies whether giving antithrombin can better prevent harmful blood clots (venous thromboembolism) after serious injuries. The goal is to reduce clot risk while you’re in the trauma ICU or step-down unit.
This trial tests whether Atenativ (an antithrombin treatment) lowers dangerous blood clots during planned surgery or during late pregnancy/delivery. It’s for people with a rare inherited blood-clotting condition called congenital antithrombin deficiency.
This study tests a blood-derived medicine (antithrombin) to help people who do not respond well to the blood thinner heparin during heart surgery. It aims to make surgery safer by improving blood thinning.
Hear when a new Antithrombinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.